论文部分内容阅读
世界上近一半的人口感染了幽门螺杆菌(Helicobacterpylori,H.pylori)。近20年的研究证实,幽门螺杆菌是慢性活动性胃炎和消化性溃疡的致病因子,而且与胃腺癌和胃粘膜组织相关性淋巴瘤(MALT)的发生密切相关。由于现行抗生素联合治疗H.pylori感染存在着耐药菌株增多和药费昂贵等问题,所以免疫防治H.pylori感染成为研究的热点,人们相继开发了蛋白组分疫苗,载体疫苗以及核酸疫苗,并在动物模型上证实有免疫保护作用,同时对H.pylori疫苗免疫
Nearly half of the world’s population is infected with Helicobacterpylori (H.pylori). Nearly 20 years of research have confirmed that H. pylori is a causative agent of chronic active gastritis and peptic ulcer, and is closely related to the occurrence of gastric adenocarcinoma and gastric mucosa-associated lymphoma (MALT). Due to the existing antibiotic combination therapy of H.pylori infection, there are many problems such as the increase of drug-resistant strains and the high cost of drugs, so immune prevention and treatment of H.pylori infection has become the focus of research. People have successively developed protein component vaccine, vector vaccine and nucleic acid vaccine In animal models confirmed immune protection, while the H.pylori vaccine immunization